Skip to main content

Drug Interactions between probenecid and seladelpar

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

probenecid seladelpar

Applies to: probenecid and seladelpar

GENERALLY AVOID: Concomitant administration with inhibitors of the organic anion transporter 3 (OAT3) may increase the plasma concentrations of seladelpar, which is a substrate of this renal transporter. Administration of the OAT3 inhibitor probenecid (500 mg four times daily) to healthy subjects on days 1 through 4, with a single dose of seladelpar (10 mg) administered on day 2 resulted in an increase of seladelpar's systemic exposure (AUC) and maximum plasma concentration (Cmax) of 2- and 4.69-fold, respectively. Additionally, the mean cumulative urinary excretion of seladelpar was unquantifiable in the presence of probenecid, compared to 2.1 mcg in the absence of probenecid.

MANAGEMENT: Concurrent use of seladelpar with OAT3 inhibitors should generally be avoided.

References (2)
  1. (2024) "Product Information. Livdelzi (seladelpar)." Gilead Sciences
  2. Cymabay Therapeutics Inc (2024) Center for drug evaluation and research. Application Number: 217899Orig1s000 integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217899Orig1s000IntegratedR.pdf

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer